XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 701-705

  Zhang, Tian ^a   Sun, Jing ^b   Lv, Min ^b   Zhang, Lin ^a   Wang, Xia ^c   Ren, Ji Chen ^d   Wang, Bin ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

^d Jilin Tumor Hospital   (China)

Author keywords

Chemotherapy; Non small cell lung cancer; Response; Xeroderma pigmentosum group G

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DNA BINDING PROTEIN; DNA EXCISION REPAIR PROTEIN ERCC 5; DNA EXCISION REPAIR PROTEIN ERCC-5; DRUG DERIVATIVE; ENDONUCLEASE; GEMCITABINE; NAVELBINE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER; VINBLASTINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 84877648854     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.701     Document Type: Article

References (23)

1. Bartolucci R, Wei J, Sanchez JJ, et al. (2009). XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer, 10, 47-52.
2. Chang JS, Wrensch MR, Hansen HM,et al. (2008) Nucleotide excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African Americans. Int J Cancer, 123, 2095-104.
3. Chen J, Xie F, Chen K,et al. (2009). ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Cancer Biol Ther, 8, 1424-30.
4. Clarkson SG (2003). The XPG story. Biochimie, 85, 1113-21.
5. Cordonnier AM, Fuchs RP (1999). Replication of damaged DNA: molecular defect in xeroderma pigmentosum variant cells. Mutat Res, 435, 111-9.
6. Fleming ND, Agadjanian H, Nassanian H,et al. (2012). Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer, 118, 689-97.
7. Friedberg EC, Bond JP, Burns DK,et al. (2000). Defective nucleotide excision repair in XPC mutant mice and its association with cancer predisposition. Mutat Res, 459, 99-108.
8. Friedberg EC (2003). DNA damage and repair. Nature, 421, 436-40.
9. Jemal A, Thomas A, Murray T, et al (2002). Cancer statistics, 2002. CA Cancer J Clin, 52, 23-47.
10. He C, Duan Z, Li P, Xu Q,et al. (2013). Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs, 24, 300-5.
11. He J, Qiu LX, Wang MY,et al. (2012). Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet, 131, 1235-44.
12. Liu D, Wu HZ, Zhang YN,et al. (2012). DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog, 51, E83-93.
13. International Agency for Research on Cancer (2008). Lung cancer incidence, Mortality and Prevalence Worldwide in 2008. http://globocan.iarc.fr/factsheet.asp.
14. Molina JR, Yang P, Cassivi SD,et al. (2008). Non-small cell lung cancer:epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94.
15. Mudgett JS, MacInnes MA (1990). Isolation of the functional human excision repair gene ERCC5 by intercosmid recombination. Genomics, 8, 623-33.
16. Nouspikel T, Lalle P, Leadon SA, Cooper PK, Clarkson SG (1997). A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function. Proc Natl Acad Sci U S A, 94, 3116-21.
17. Sakano S, Hinoda Y, Sasaki M,et al. (2010). Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics, 11, 1377-87.
18. Sun X, Li F, Sun N,et al. (2009). Polymorphisms in XRCC1 and XPG and response to platinumbased chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 65, 230-6.
19. Tahara E, Yasui W, Ito H,et al. (2009). Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium. Jpn J Clin Oncol, 40, 702-8.
20. Takahashi E, Shiomi N, Shiomi T (1992). Precise localization of the excision repair gene, ERCC5, to human chromosome 13q32.3- q33.1 by direct R-banding fluorescence in situ hybridization. Jpn J Cancer Res, 83, 1117-9.
21. Walsh CS, Ogawa S, Karahashi H,et al. (2008). ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol, 26, 2952-8.
22. Wood RD, Mitchell M, Sgouros J,et al. (2001) Human DNA repair genes. Science, 291, 1284-9.
23. Zhang L, Gao G, Li X,et al. (2012). Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS One, 7, e48350.